Therapeutic Peptides for Cardiovascular Disease and Cancer Cam Patterson, MD, MBA, FACC, FAHA Ernest...

6
Therapeutic Peptides for Therapeutic Peptides for Cardiovascular Disease and Cardiovascular Disease and Cancer Cancer Cam Patterson, MD, MBA, FACC, FAHA Ernest and Hazel Craige Distinguished Professor of Cardiovascular Medicine Chief, Division of Cardiology Director, Carolina Cardiovascular Biology Center University of North Carolina at Chapel Hill Anka N. Veleva, PhD, MA Department of Chemical and Biomolecular Engineering North Carolina State University Stuart L. Cooper, PhD Department of Chemical and Biomolecular Engineering Ohio State University
  • date post

    21-Dec-2015
  • Category

    Documents

  • view

    214
  • download

    0

Transcript of Therapeutic Peptides for Cardiovascular Disease and Cancer Cam Patterson, MD, MBA, FACC, FAHA Ernest...

Page 1: Therapeutic Peptides for Cardiovascular Disease and Cancer Cam Patterson, MD, MBA, FACC, FAHA Ernest and Hazel Craige Distinguished Professor of Cardiovascular.

Therapeutic Peptides forTherapeutic Peptides forCardiovascular Disease and CancerCardiovascular Disease and Cancer

Cam Patterson, MD, MBA, FACC, FAHAErnest and Hazel Craige Distinguished Professorof Cardiovascular MedicineChief, Division of CardiologyDirector, Carolina Cardiovascular Biology CenterUniversity of North Carolina at Chapel Hill

Anka N. Veleva, PhD, MADepartment of Chemical andBiomolecular EngineeringNorth Carolina State University

Stuart L. Cooper, PhDDepartment of Chemical andBiomolecular EngineeringOhio State University

Page 2: Therapeutic Peptides for Cardiovascular Disease and Cancer Cam Patterson, MD, MBA, FACC, FAHA Ernest and Hazel Craige Distinguished Professor of Cardiovascular.

Endothelial Progenitor Cells (EPC)Endothelial Progenitor Cells (EPC)from Biology to Treatmentfrom Biology to Treatment

□□ In 1997, EPC were first identified in adult human peripheral blood

□□ EPC are immature cells capable of differentiating into mature endothelial cells

□□ EPC can play an important role in the formation of new blood vessels - mobilization from the bone marrow

- migration through the circulation - incorporation into blood vessels

□□ Clinically, the number and function of EPC

have been positively linked with improved endothelial function and regeneration

Rosenzweig A., Rosenzweig A., NEJMNEJM, , 348348, 581 (2003)., 581 (2003).

Page 3: Therapeutic Peptides for Cardiovascular Disease and Cancer Cam Patterson, MD, MBA, FACC, FAHA Ernest and Hazel Craige Distinguished Professor of Cardiovascular.

Phage Display Technology to Identify PeptidesPhage Display Technology to Identify PeptidesSpecific for Endothelial Progenitor CellsSpecific for Endothelial Progenitor Cells

Veleva A. et al., Biotechnology and Bioengineering, 98, 306 (2007).

Page 4: Therapeutic Peptides for Cardiovascular Disease and Cancer Cam Patterson, MD, MBA, FACC, FAHA Ernest and Hazel Craige Distinguished Professor of Cardiovascular.

Peptides Immobilized on a Biomaterial Scaffold to Peptides Immobilized on a Biomaterial Scaffold to Improve Cyto- and Blood- compatibility of ImplantsImprove Cyto- and Blood- compatibility of Implants

Veleva A. et al., Biomaterials, 29, 3656 (2008).

□ □ Stimulating endothelialization at the implant Stimulating endothelialization at the implant surface will restore vascular homeostasis surface will restore vascular homeostasis earlyearly in the healing process in the healing process

Page 5: Therapeutic Peptides for Cardiovascular Disease and Cancer Cam Patterson, MD, MBA, FACC, FAHA Ernest and Hazel Craige Distinguished Professor of Cardiovascular.

New Functional Tools to Target Tumor Vasculature New Functional Tools to Target Tumor Vasculature

□□ Tumor angiogenesis has a critical role in promoting the growth of most carcinomas

□□ EPC play an important role in angiogenesis-mediated tumor progression

□□ To utilize endogenous EPC as natural vectors to deliver diagnostic and therapeutic reagents to tumors

Page 6: Therapeutic Peptides for Cardiovascular Disease and Cancer Cam Patterson, MD, MBA, FACC, FAHA Ernest and Hazel Craige Distinguished Professor of Cardiovascular.

Market PotentialMarket Potential

□□ Regenerative Medicine

- cell separations- production of pure cell populations for allogeneic stem cell therapies

□□ Medical Implant Technologies to treat cardiovascular diseases, “off-the-shelf” products

- innovative intravascular stent systems- small diameter vascular grafts- pacemakers- heart valve repair- arterial septal repair implants

□□ Oncology - targeting of tumor-associated blood vessels

- non-invasive detection of small cancer tissue, primary tumors & metastases- targeted therapeutics, development of highly specific drug delivery systems- personalized medicine, monitoring efficacy of therapies